| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Klee Justin B. | Co-Chief Executive Officer, Director | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE | /s/ Joshua B. Cohen, as Attorney in Fact | 02 Oct 2025 | 0001898314 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMLX | Common Stock | Sale | $427,950 | -29,775 | -0.89% | $14.37 | 3,325,501 | 30 Sep 2025 | Direct | F1, F2 |
| transaction | AMLX | Common Stock | Sale | $3,002 | -200 | -0.01% | $15.01 | 3,325,301 | 30 Sep 2025 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.99 to $14.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |